

CURRICULUM VITAE DE LUCIA ANNA

Personal Information

- **Name:** Anna De Lucia
- **Date of birth:** 21/01/1997
- **Nationality:** Italian
- **Email:** anna.delucia@irst.emr.it
- **ORCID:** <https://orcid.org/0000-0002-3128-9738>

Current Position

- **PhD Candidate in Translational Immuno-Oncology**
Department of Biomedical and Neuromotor Sciences (DIBINEM), University of Bologna.
Research conducted at Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy

PhD fellowship under **D.M. 352/2022**, funded by the **European Union – NextGenerationEU**, National Recovery and Resilience Plan (PNRR), Mission 4, Component 2, Investment 3.3, and co-funded by IRST “Dino Amadori”.

Education

- **PhD in Biomedical and Neuromotor Sciences** (*ongoing*)
University of Bologna, Italy. *November 2022 – present*
Thesis title: “*TRBC1-directed CAR-T-One cells for the treatment of T-cell malignancies: preclinical characterization, safety assessment, and translational feasibility*”
- **MSc in Functional Genomics** (*with full marks*)
University of Trieste, Italy. *October 2019 – March 2022*
Master’s thesis: “*CD4 CAR-T cells drive extensive CD8 CAR-T cells expansion, leading to severe Cytokine Release Syndrome*”
Conducted at IRCCS Ospedale San Raffaele, Milan, Innovative Immunotherapies Unit (Dr. Monica Casucci)
- **BSc in Biology**
University of Urbino “Carlo Bo”, Italy. *October 2016 – October 2019*

Research Experience

- **Doctoral Researcher.**

Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy.
November 2022 – present

Development and preclinical evaluation of TRBC1-directed CAR-T therapy (CAR-T-One) for T-cell malignancies
- **Visiting PhD Researcher (International Mobility Period).**

Hospital Clínic de Barcelona / IDIBAPS. Immunogenetics and Immunotherapy in Autoinflammatory and Immune Responses Group. Supervisor: Dr. Hugo Calderón. Group leader: Prof. Juan Manuel Otero. *July 2024 – January 2025*

- Participation in **GMP-compliant lentiviral vector manufacturing** for CAR-T applications

- **Postgraduate Research Trainee.**

IRST “Dino Amadori”, Meldola, Italy. *April 2022 – November 2022*

- **Research Intern – Innovative Immunotherapies Unit.**

IRCCS Ospedale San Raffaele, Milan. *March 2021 – March 2022*

- CAR-T cell biology, CD4/CD8 subset interactions
- Cytokine release syndrome mechanisms
- Humanized mouse models (SGM3)

Publications

1. **De Lucia A**, Mazzotti L, Gaimari A, Zurlo M, Maltoni R, Cerchione C, Bravaccini S, Delmonte A, Crinò L, Borges de Souza P, Pasini L, Nicolini F, Bianchi F, Juan M, Calderon H, Magnoni C, Gazzola L, Ulivi P, Mazza M. Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy. *Front Immunol.* 2025 Feb 10;16:1515748. doi: 10.3389/fimmu.2025.1515748. PMID: 39995659; PMCID: PMC11847692.
2. Nicolini F, Gaimari A, Mazzotti L, **De Lucia A**, Ghirelli M, Ancarani V, Borges de Souza P, Zurlo M, Gazzola L, Magnoni C, Capobianco S, Angeli D, Bravaccini S, Cerchione C, Guidoboni M, Lanfranccone L, Marocchi F, Maltoni R, Tumedei MM, Limarzi F, Pasini L, Ridolfi L, Mazza M. Circulating memory B-cell receptor repertoire analysis identifies novel candidate antibodies against metastatic melanoma in immunotherapy-responsive patients. *Front Immunol.* 2025 Oct 9;16:1636722. doi: 10.3389/fimmu.2025.1636722. PMID: 41142822; PMCID: PMC12548061.
3. Bravaccini S, Nicolini F, Balzi W, Azzali I, Pasini L, Mazzotti L, Gaimari A, **De Lucia A**, Zurlo M, Maltoni R, Pirini F, Cortesi M, Zanoni M, Tumedei MM, Nanni O, Cerchione C, Sambri V, de Souza PB, Martinelli G, Mazza M. First real-world evidence from the Emilia-Romagna region suggests tamoxifen protects breast cancer patients from COVID-19. *Sci Rep.* 2025 Nov 5;15(1):38742. doi: 10.1038/s41598-025-22463-8. PMID: 41193536; PMCID: PMC12589471.
4. Nicolini F, Naranjo Gomez M, Pelegrin M, **De Lucia A**, Mazzotti L, Mazza M. Editorial: New avenues for the development of advanced immunotherapies: capitalizing on studies of the B and T cell receptor repertoire. *Front Immunol.* 2025 Oct 2;16:1693587. doi: 10.3389/fimmu.2025.1693587. PMID: 41112242; PMCID: PMC12528009.
5. Gaimari A, **De Lucia A**, Nicolini F, Mazzotti L, Maltoni R, Rughi G, Zurlo M, Marchesini M, Juan M, Parras D, Cerchione C, Martinelli G, Bravaccini S, Tettamanti S, Pasetto A, Pasini L, Magnoni C, Gazzola L, Borges de Souza P, Mazza M. Significant Advancements and Evolutions in Chimeric Antigen Receptor Design. *Int J Mol Sci.* 2024 Nov 13;25(22):12201. doi: 10.3390/ijms252212201. PMID: 39596267; PMCID: PMC11595069.
6. Bove C, Arcangeli S, Falcone L, Camisa B, El Khoury R, Greco B, **De Lucia A**, Bergamini A, Bondanza A, Ciceri F, Bonini C, Casucci M. CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term responses. *J Immunother Cancer.* 2023 Jan;11(1):e005878. doi: 10.1136/jitc-2022-005878. PMID: 36593069; PMCID: PMC9809278.

7. Liverani C, De Vita A, Spadazzi C, Miserocchi G, Cocchi C, Bongiovanni A, **De Lucia A**, La Manna F, Fabbri F, Tebaldi M, Amadori D, Tasciotti E, Martinelli G, Mercatali L, Ibrahim T. Lineage-specific mechanisms and drivers of breast cancer chemoresistance revealed by 3D biomimetic culture. *Mol Oncol.* 2022 Feb;16(4):921-939. doi: 10.1002/1878-0261.13037. Epub 2021 Jul 10. PMID: 34109737; PMCID: PMC8847989.

Scientific Meetings and Training

(Selection, from February 2022)

- EBMT–EHA European CAR T-Cell Meetings (2022, 2023, 2024, 2026)
- IV Italian Congress of Advanced Therapy, Rimini, 2024
- SOHO Italy Annual Conference, Rome, 2025
- ESGCT/SETGYC Collaborative Congress, Seville, 2025
- Certified courses on animal experimentation (DM 5 August 2021)
- GCP, laboratory safety, clinical research regulations

Conference Abstracts, Posters, and Oral Presentations

Poster presentations

- Characterizing Human NSCLC Targeting Antibodies through In Situ BCR Repertoire Analysis.
Poster presented at the 8th Annual Meeting of Alleanza Contro il Cancro (ACC) – Italian Ministry of Health Oncology Network, September 27–29, 2023, Policlinico IRCCS San Martino, Genoa, Italy.
- Evaluation of efficacy of a TCR beta constant region 1 (TRBC1)-directed Chimeric Antigen Receptor (CAR) against T-ALL and T-cell lymphoma.
Poster presented at the 9th Annual Meeting of Alleanza Contro il Cancro (ACC), November 28–30, 2024, Reggio Emilia, Italy.
- Evaluation of efficacy of a TCR beta constant region 1 (TRBC1)-directed Chimeric Antigen Receptor (CAR) and Bi-specific T-cell engager (BiTE) against T-ALL and T-cell lymphoma.
Poster presented at the IV Italian Conference on Advanced Therapies and Radiopharmaceuticals, September 25–27, 2024, Centro Congressi SGR, Rimini, Italy.
- Effectiveness assessment of a TRBC1-directed chimeric antigen receptor against T-acute lymphoblastic leukemia and T-cell lymphoma.
Poster presented at the 6th SOHO Italy Annual Hybrid Conference, February 25–26, 2025, Rome, Italy. (Associated oral presentation delivered by the Principal Investigator of the group).
- Development and evaluation of a TRBC1-targeted CAR-T therapy for T-cell malignancies.
Poster presented at the 32nd ESGCT Annual Congress, October 7–10, 2025, FIBES Conference Centre, Seville, Spain.

Oral presentations

- Selective Targeting of T-Cell Malignancies Using a TRBC1-Directed CAR T-Cell Therapy. Oral Presentation at the 8th EBMT–EHA European CAR T-Cell Meeting, February 12–14, 2026, Palma de Mallorca, Spain.

Awards & Recognitions

- Finalist – 6th Emerging Investigators EBMT-EHA Joint Fellowship Award, 8th EBMT–EHA European CAR T-Cell Meeting, 2026. Selected for Oral Presentation in the Clinical Track (CAR-based Cellular Therapy – Clinical).

Invited Media Contributions

- Invited Speaker Interview – VJHemOnc Coverage of the EBMT–EHA 8th European CAR T-Cell Meeting, 2026. Available at: <https://www.vjhemonc.com/speaker/anna-de-lucia/>

Patents and Translational Activities

Patent

LUNG CANCER TARGETING HUMAN ANTIBODIES AND THERAPEUTIC USES THEREOF (WO2024/188790; 2023)

Startup pitches and innovation programs (related to patents)

- PerfeTTO Match-Up 2025, Milan, Italy – Startup pitch presentation (TriBILife).
- Deloitte Startup Aquarium, January 2025, Milan, Italy – Startup pitch presentation (TriBILife).
- StartUp Academy – Life Science, January 2025, Catania, Italy – *Winner*. Startup pitch presentation and participation in the innovation program (TriBILife).

Professional Memberships

- Registered Biologist – Italian National Order of Biologists (Section A)

I consent to the processing of personal data contained in my curriculum vitae on the basis of Legislative Decree 196/2003, integrated with the amendments introduced by Legislative Decree 101/2018, and art. 13 of the GDPR (EU Regulation 2016/679).

Aware that - pursuant to art. 76 of Presidential Decree 445/2000 - false declarations, false documents and the use of false documents are punished pursuant to the penal code and special laws, I declare that the information is true.

Firma 